Cancer Genomics: Large-Scale Projects Translate into Therapeutic Advances. by Elaine R Mardis, Marc Ladanyi

Get full text

Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma by Marc Ladanyi, Francisco Sanchez Vega, Marjorie Zauderer

Get full text

BAP1 missense mutation c.2054 A>T (p.E685V) completely disrupts normal splicing through creation of a novel 5' splice site in a human mesothelioma cell line. by Arianne Morrison, Yvonne Chekaluk, Ruben Bacares, Marc Ladanyi, Liying Zhang

Get full text

Functional copy-number alterations in cancer. by Barry S Taylor, Jordi Barretina, Nicholas D Socci, Penelope Decarolis, Marc Ladanyi, Matthew Meyerson, Samuel Singer, Chris Sander

Get full text

Somatic intronic TP53 c.375+5G mutations are a recurrent but under‐recognized mode of TP53 inactivation by M Herman Chui, Ciyu Yang, Nikita Mehta, Vikas Rai, Ahmet Zehir, Amir Momeni Boroujeni, Marc Ladanyi, Diana Mandelker

Get full text

Integrative subtype discovery in glioblastoma using iCluster. by Ronglai Shen, Qianxing Mo, Nikolaus Schultz, Venkatraman E Seshan, Adam B Olshen, Jason Huse, Marc Ladanyi, Chris Sander

Get full text

Desmoplastic small round cell tumor cancer stem cell-like cells resist chemotherapy but remain dependent on the EWSR1-WT1 oncoprotein by Justin W. Magrath, Hong-Jun Kang, Alifiani Hartono, Madelyn Espinosa-Cotton, Romel Somwar, Marc Ladanyi, Nai-Kong V. Cheung, Sean B. Lee

Get full text

Extracellular signal-regulated kinase mediates chromatin rewiring and lineage transformation in lung cancer by Yusuke Inoue, Ana Nikolic, Dylan Farnsworth, Rocky Shi, Fraser D Johnson, Alvin Liu, Marc Ladanyi, Romel Somwar, Marco Gallo, William W Lockwood

Get full text

Uterine mesenchymal tumors harboring ALK fusions and response to ALK-targeted therapy by Chrisann Kyi, Claire F. Friedman, Jennifer J. Mueller, Ryma Benayed, Marc Ladanyi, Maria Arcila, Soo Ryum Yang, Martee L. Hensley, Sarah Chiang

Get full text

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. by William Pao, Theresa Y Wang, Gregory J Riely, Vincent A Miller, Qiulu Pan, Marc Ladanyi, Maureen F Zakowski, Robert T Heelan, Mark G Kris, Harold E Varmus

Get full text

TP53 exon-6 truncating mutations produce separation of function isoforms with pro-tumorigenic functions by Nitin H Shirole, Debjani Pal, Edward R Kastenhuber, Serif Senturk, Joseph Boroda, Paola Pisterzi, Madison Miller, Gustavo Munoz, Marko Anderluh, Marc Ladanyi, Scott W Lowe, Raffaella Sordella

Get full text

High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). by Yixuan Gong, Evelyn Yao, Ronglai Shen, Aviva Goel, Maria Arcila, Julie Teruya-Feldstein, Maureen F Zakowski, Stanley Frankel, Martin Peifer, Roman K Thomas, Marc Ladanyi, William Pao

Get full text

Correction: TP53 exon-6 truncating mutations produce separation of function isoforms with pro-tumorigenic functions by Nitin H Shirole, Debjani Pal, Edward R Kastenhuber, Serif Senturk, Joseph Boroda, Paola Pisterzi, Madison Miller, Gustavo Munoz, Marko Anderluh, Marc Ladanyi, Scott W Lowe, Raffaella Sordella

Get full text

DOK2 inhibits EGFR-mutated lung adenocarcinoma. by Alice H Berger, Ming Chen, Alessandro Morotti, Justyna A Janas, Masaru Niki, Roderick T Bronson, Barry S Taylor, Marc Ladanyi, Linda Van Aelst, Katerina Politi, Harold E Varmus, Pier Paolo Pandolfi

Get full text

MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppression by Dylan A. Farnsworth, Yusuke Inoue, Fraser D. Johnson, Georgia de Rappard-Yuswack, Daniel Lu, Rocky Shi, Lok In Josephine Ma, Marissa S. Mattar, Romel Somwar, Marc Ladanyi, Arun M. Unni, William W. Lockwood

Get full text

NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors by Romel Somwar, Nicolle E. Hofmann, Bryan Smith, Igor Odintsov, Morana Vojnic, Irina Linkov, Ashley Tam, Inna Khodos, Marissa S. Mattar, Elisa de Stanchina, Daniel Flynn, Marc Ladanyi, Alexander Drilon, Ujwal Shinde, Monika A. Davare

Get full text

Maximizing the clinical utility and performance of cytology samples for comprehensive genetic profiling by David Kim, Chad M. Vanderbilt, Soo-Ryum Yang, Subhiksha Nandakumar, Khedoudja Nafa, Rusmir Feratovic, Natasha Rekhtman, Ivelise Rijo, Jacklyn Casanova, Anita Yun, A. Rose Brannon, Michael F. Berger, Marc Ladanyi, Oscar Lin, Maria E. Arcila

Get full text

Salt-Inducible Kinase 1 is a potential therapeutic target in Desmoplastic Small Round Cell Tumor by Alifiani Bonita Hartono, Hong-Jun Kang, Lawrence Shi, Whitney Phipps, Nathan Ungerleider, Alexandra Giardina, WeiPing Chen, Lee Spraggon, Romel Somwar, Krzysztof Moroz, David H. Drewry, Matthew E. Burow, Erik Flemington, Marc Ladanyi, Sean Bong Lee

Get full text

Antibiotics are associated with worse outcomes in lung cancer patients treated with chemotherapy and immunotherapy by Arielle Elkrief, Eder Orlando Méndez-Salazar, Jade Maillou, Chad M. Vanderbilt, Pooja Gogia, Antoine Desilets, Meriem Messaoudene, Daniel Kelly, Marc Ladanyi, Matthew D. Hellmann, Laurence Zitvogel, Charles M. Rudin, Bertrand Routy, Lisa Derosa, Adam J. Schoenfeld

Get full text

Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing by Donavan T. Cheng, Meera Prasad, Yvonne Chekaluk, Ryma Benayed, Justyna Sadowska, Ahmet Zehir, Aijazuddin Syed, Yan Elsa Wang, Joshua Somar, Yirong Li, Zarina Yelskaya, Donna Wong, Mark E. Robson, Kenneth Offit, Michael F. Berger, Khedoudja Nafa, Marc Ladanyi, Liying Zhang

Get full text